NCT06086522 Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
| NCT ID | NCT06086522 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Qualigen Theraputics, Inc. |
| Condition | Solid Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 54 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 54 participants in total. It began in 2023-11-01 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patient.
Eligibility Criteria
Inclusion Criteria: * Patients with histologically confirmed locally advanced or metastatic solid carcinomas, who have had tumor progression after receiving all standard of care therapies or for which there is no approved therapy 2. Evaluable or measurable disease by RECIST 1.1 Exclusion Criteria: \-
Contact & Investigator
Tariq Arshad, MD
STUDY DIRECTOR
Qualigen Theraputics, Inc.
Frequently Asked Questions
Who can join the NCT06086522 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Solid Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06086522 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06086522 currently recruiting?
Yes, NCT06086522 is actively recruiting participants. Contact the research team at clinicaltrials@qlgntx.com for enrollment information.
Where is the NCT06086522 trial being conducted?
This trial is being conducted at Scottsdale, United States, New Haven, United States, Grand Rapids, United States, Houston, United States.
Who is sponsoring the NCT06086522 clinical trial?
NCT06086522 is sponsored by Qualigen Theraputics, Inc.. The principal investigator is Tariq Arshad, MD at Qualigen Theraputics, Inc.. The trial plans to enroll 54 participants.